Phase II multicenter, double-blind, randomized controlled trial of FOLFOX therapy with bevacizumab in patients with unresectable advanced / recurrent small bowel cancer

Interventions: Eligible cases are assigned to the Bev + FOLFOX group or the placebo + FOLFOX group. In principle, one cycle should be 14 days, and the investigational drug (bevacizumab or placebo) should be administered on Day 1 of mFOLFOX6. Bevacizumab is administered by mixing 5 mg / kg (body weight) into physiological saline at a time. Placebo is given 100 mL of saline. The frequency of administration of the investigational drug is not specified.
Primary outcome(s): Progression Free Survival (PFS)
Study Design: randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose